See the long-term (lifetime) effects of dapagliflozin in chronic kidney disease: a time-to-event analysis https://t.co/KB1IAkebwp @Stenodiabetes@NDTsocial
Will ADCs integrate into or replace the current standard of care in metastatic diseases?
The insights to this and many more came from the AZ and DS sponsored ESMO coloquim at ESMO 2023 conference in Madrid Spain #esmo2023#raslss#oncology
🌟September is Ovarian Cancer Awareness Month 🌟
Let's come together this September to amplify the message of ovarian cancer awareness.
Watch this video to learn more.... #ovariancancer#oncology#CancerResearch#raslss
However, gaps still exist. Inga Drossart at #esc2023 presented a complex yet comprehensive picture of the #digitaldivide that still exists with #design and #interoperability as two major issues (among others) that adversely affect the uptake of devices in healthcare
Some hard evidence of the utility of #wearables was presented by Prof. Svennberg in her #digitalhealth talk at #esc2023. The studies are small but the meta-analysis gives us a positive indicator that the #wearables do encourage physical activity.
There are multiple opportunities for digital technologies to improve #patientcare. Prof. Svennberg summarized it succinctly in a single diagram in a #digitalhealth talk at #esc2023
The ability to measure BP, by the minute will open up immense avenues of research on patient risk stratification and possibly catching asymptomatic individuals much before it’s too late! #ESC2023
A fascinating lecture by Prof. Hae-Young Lee on CART ring device for continuous non-intrusive BP monitoring, at #ESC2023. This device might just open a new area of research Dynamic BP monitoring for superior CV risk prediction and treatment optimization.
Another exciting session of #digitalhealth at #ESC2023 - a quick history of #bpmonitoring…what a long way we have come from the first sphygmomanometer in 1830s to cuffless connected wearables of today
July is Sarcoma Awareness Month, a time to raise awareness of this rare type of cancer. Sarcomas are often referred to as the "forgotten cancer" because they are relatively rare
Together, we can raise awareness of this rare cancer and help to find a cure #dyk#dykfacts#oncology
Sharing the 5th episode of our monthly #KnowYourTrial series, where we provide the therapy area distribution and key drug classes of the assets entering #clinicaldevelopment in May 2023. Follow us for more
We are back with the 4th episode of the #KnowYourTrial series, where we give you #insights on the de novo assets that have entered #clinicaldevelopment in the US #clinicaltrial registry. Check out the therapy area and key drug class distribution in April 2023. Stay tuned for more
#Didyouknow, May is #bladdercancer awareness month? In the US alone, there are ~82,290 new cases and ~16,710 deaths annually. Treatment depends on the stage of the #cancer . Early detection/treatment are crucial for better outcomes. Check out our video to know more #raslss#DYK